Apimeds Pharmaceuticals, a Matawan company, recently announced a merger with MindWave Innovations, aimed at improving biopharmaceutical innovation and digital-asset financial technology.
The merger will be supported by a simultaneous PIPE of up to $100 million to advance Apimeds’ clinical programs and expand MindWave’s digital asset infrastructure.
MindWave is a global leader in AI-driven Bitcoin and yield-generation technologies, with its platform is designed to help institutions securely hold, manage, and generate yield from Bitcoin reserves.
Apimeds focuses on developing non-opioid, biologic-based therapies for pain management. Its lead product candidate, Apitox, is in late-stage clinical development for the treatment of knee osteoarthritis.
MindWave’s three-pronged strategic framework includes:
- Secure Digital Treasury Wallets for Corporations,
- AI-Enhanced Bitcoin Yield Generation, and
- A Validator-Powered Ecosystem supported by the $NILA Token.
Apimeds CEO Erik Emerson explained the financial move.
“As Apimeds moves toward its Phase 3 clinical trial initiation, we continue to focus on financing and expansion,” he said. “When I met the leadership team at MindWave and saw the strength and scalability of their business, it became clear this merger represented a unique opportunity. Biotech requires significant capital, and integrating a high-yield digital asset business with strong cash-flow potential will allow us to accelerate our therapeutic programs.”
E.F. Hutton & Co. served as the exclusive M&A advisor to Apimeds and MindWave in connection with the merger, and as the exclusive placement agent for the concurrent PIPE of up to $100 million in financing.
